ANI Pharmaceuticals Offers to Acquire Egetis
The $1.13-per-share cash offer carries a 27% premium to Egetis's 60-day volume-weighted average price.
Updated on Nov. 5, 2026 in Healthcare
Live Poll
Do you trust big drug companies to put patients ahead of profits when they buy smaller firms?
ANI Pharmaceuticals has sent a recommended public offer to acquire Egetis Therapeutics AB, valued at approximately $560 million including outstanding incentive programs. Egetis's board unanimously recommends that shareholders accept the offer.
Why it matters
The offer would give Egetis access to ANI's established rare disease platform and U.S. commercialization capabilities to expand patient access to Emcitate. The deal also follows Egetis's sale of its Rare Pediatric Disease Priority Review Voucher for $190 million.
The offer carries a $1.13-per-share cash price, a 27% premium to the 60-day volume-weighted average price, and an enterprise value of approximately $434 million. Shareholders representing about 42% of outstanding shares have undertaken to accept, but the 90% acceptance threshold and regulatory approvals remain outstanding.
The players
ANI Pharmaceuticals
ANI Pharmaceuticals is a U.S.-based specialty pharmaceutical company with an established rare disease platform and commercialization capabilities in the United States.
Egetis Therapeutics AB
Egetis Therapeutics is a Swedish biopharmaceutical company focused on rare diseases, and it developed Emcitate, the first approved treatment for MCT8 deficiency.
The details
The offer is financed through cash on hand and new debt from JPMorgan Chase Bank, N.A. Upon closing, former owners of RTTI are entitled to approximately 50% of net proceeds from the voucher as an earn-out tied to Egetis's 2020 acquisition of Emcitate.
Timeline
February 12, 2025: The European Commission approved Emcitate.
September 28, 2026: The FDA approved Emcitate as the first and only approved treatment for peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency.
November 4, 2026: Egetis announced the priority review voucher sale agreement.
November 5, 2026: ANI announced the recommended public offer for Egetis.
On or around November 20, 2026: The acceptance period for the offer is expected to begin.
Market Landscape
The transaction shows how rare pediatric disease priority review vouchers, granted by the FDA, are being monetized alongside company acquisitions in specialty pharmaceuticals. It positions ANI to build a higher-margin rare disease portfolio as it seeks to derive a substantial majority of its revenue from such products by decade's end.
Egetis shareholders who accept would receive $1.13 per share in cash, a 27% premium to the 60-day volume-weighted average price. Closing depends on acceptance by shareholders representing at least 90% of outstanding shares and receipt of necessary regulatory approvals.
The takeaway
Rare disease drug acquisitions increasingly pair regulatory incentives such as priority review vouchers with commercial infrastructure to bring approved therapies to smaller patient populations. Shareholders weighing the offer should review the premium against the conditions for closing.
What happens next
Acceptance period for the offer is expected to begin on or around November 20, 2026, and the offer remains subject to the 90% shareholder acceptance threshold and regulatory approvals.
Further reading
For broader context on drug development and access, explore the Healthcare section.
More information
Read the ANI official offer announcement press release on ANI's investor relations site.
Live Poll
Do you trust big drug companies to put patients ahead of profits when they buy smaller firms?
